Jeremy Bender is Chief Executive Officer and President of Day One Biopharmaceuticals, Inc. (DAWN). The company reported total compensation of $6,560,577 for fiscal year 2024.
| Salary | $680,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,700,280 |
| Option awards | $2,664,697 |
| Non-equity incentive plan | $501,800 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $13,800 |
| Total | $6,560,577 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Day One Biopharmaceuticals, Inc. filed April 11, 2025, accession 0001140361-25-013462.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | Chief Executive Officer and President | $680,000 | $0 | $2,700,280 | $2,664,697 | $501,800 | $0 | $13,800 | $6,560,577 |
| FY2023 | Chief Executive Officer and President | $647,000 | $0 | $1,779,160 | $4,086,399 | $388,200 | $0 | $13,200 | $6,913,959 |
| FY2022 | Chief Executive Officer and President | $610,000 | $0 | $812,820 | $3,361,436 | $290,000 | $0 | $12,200 | $5,086,456 |
Totals as disclosed in each year's own compensation disclosure for Day One Biopharmaceuticals, Inc..
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Jeremy Bender this page | Chief Executive Officer and President | $6,560,577 |
| Charles York | Chief Operating Officer and Chief Financial Officer | $3,896,080 |
| Samuel Blackman | Co-Founder and Head of Research and Development | $3,614,904 |
| Adam Dubow | General Counsel, Chief Compliance Officer and Secretary | $2,385,614 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Day One Biopharmaceuticals, Inc. compensation brief.
Jeremy Bender's compensation sits inside Day One Biopharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Day One Biopharmaceuticals, Inc. (DAWN) compensation brief